Back to Newsroom

Apogenix’ APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fcγ Cross-Linking

Heidelberg, Germany, Dec. 5, 2013 – Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in the December issue of Molecular Cancer Therapeutics demonstrate effective antitumor activity of the company’s drug candidate APG350, an activator for TRAIL receptors. The publication shows that APG350’s novel molecular structure allows for potent induction of apoptosis of tumor cells independent of the innate immune system, thus overcoming the limitations of other TRAIL receptor agonists.